

Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

References. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. CGP agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human fetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:

John G. Delinassios
 International Institute of Anticancer Research (IIAR)
 Editorial Office of ANTICANCER RESEARCH,
 IN VIVO, CANCER GENOMICS and PROTEOMICS.
 1st km Kapandritiou-Kalamou Road
 P.O. Box 22, GR-19014 Kapandriti, Attiki
 GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies, PDF files, or/and Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2012 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

First-line Bevacizumab plus Taxane-based Chemotherapy for Metastatic Breast Cancer: Cost-minimisation Analysis. V. NERICH, F. BAZAN, F. COMPAGNAT, E. DOBI, C. VILLANUEVA, L. CHAIGNEAU, S. PERRIN, A. VOIDEY, X. PIVOT, S. LIMAT (<i>Besançon, France</i>)	3547
Efficacy of Carboplatin and Paclitaxel with Bevacizumab as Salvage Chemotherapy for Non-small Cell Lung Cancer after Failure of Platinum-doublet Chemotherapy. M. TAMIYA, A. TAMIYA, K. NAKAO, K. ASAMI, K. OKISHIO, M. SATOMU, T. SHIROYAMA, N. MORISHITA, H. SUZUKI, S. SASADA, N. OKAMOTO, K. OKISHIO, T. KAWAGUCHI, M. KOBAYASHI, S. ATAGI, T. HIRASHIMA, I. KAWASE (<i>Osaka; Tokyo, Japan</i>).....	3553
Association Between COX-2 Expression and Effectiveness of COX-2 Inhibitors in a Phase II Trial in Patients with Metastatic Colorectal Adenocarcinoma. K. ALMHANNA, B. EL-RAYES, S. SETHI, G. DYSON, L. HEILBRUN, P.A PHILIP, F. SARKAR (<i>Tampa, FL; Atlanta, GA; Detroit, MI, USA</i>)	3559
Circulating Vascular Endothelial Growth Factor in Childhood Solid Tumors: Plasma and Serum Measurements. A. SCHIAVETTI, A. INGROSSO, A. ANTENUCCI, T. FEDERICI, G. MEGARO, L. DE LUCA, L. CONTI (<i>Rome, Italy</i>).....	3565
Predictive Factors for Breast Cancer in Patients Diagnosed with Ductal Intraepithelial Neoplasia, Grade 1B. S. BENDIFALLAH, N. CHABBERT-BUFFET, N. MAURIN, J. CHOPIER, M. ANTOINE, C. BEZU, S. UZAN, R. ROUZIER (<i>Paris, France</i>)	3571
Applicability of Histoculture Drug Response Assays in Colorectal Cancer Chemotherapy. Y.S. YOON, C.W. KIM, S.A. ROH, D.H. CHO, G.P. KIM, Y.S. HONG, T.W. KIM, M.B. KIM, J.C. KIM (<i>Seoul; Gyeonggi-do, Republic of Korea</i>)	3581
Effect of Serum Selenium Levels on Radiotherapy-related Toxicity in Patients Undergoing Radiotherapy for Head and Neck Cancer. C. EROGLU, D. UNAL, A. CETİN, O. ORHAN, S. SIVGIN, A. OZTÜRK (<i>Kayseri, Turkey</i>).....	3587
Appendix to Anticancer Research Volume 32, No 5, pp. 1843-1966	3591
Errata	3592
Retraction	3593
Book Reviews	3594
Announcements	3600
* Reviews (pages 3045, 3077, 3223, 3235)	

The Functional Polymorphism of Erythropoietin Gene rs1617640 G>T Is Not Associated with Susceptibility and Clinical Outcome of Early-stage Breast Cancer. J. SZKANDERA, G. ABSENGER, M. STOTZ, M. WEISSMUELLER, T. WINDER, T. LANGSENLEHNER, H. SAMONIGG, W. RENNER, W. SCHIPPINGER, A. GERGER (<i>Graz; Feldkirch, Austria</i>)	3473
Enhanced Expression of Peroxisome Proliferate-activated Receptor Gamma (PPAR- γ) in Advanced Prostate Cancer. S. ROGENHOFER, J. ELLINGER, P. KAHL, C. STOEHR, A. HARTMANN, D. ENGEHAUSEN, W.-F. WIELAND, S.C. MÜLLER, F. HOFSTÄDTER, B. WALTER (<i>Bonn; Cologne; Erlangen; Regensburg, Germany</i>)	3479
Estrogen Receptor, Progesterone Receptor, and Nuclear Size Features in Female Breast Cancer in Libya: Correlation with Clinical Features and Survival. F.B. ABDALLA, R. MARKUS, A. BUHMEIDA, J. BODER, K. SYRJÄNEN, Y. COLLAN (<i>Turku, Finland; Misurata; Tripoli, Libya; Jeddah, Saudi Arabia</i>)	3485
Effects of Intermittent 5-Fluorouracil and Low-dose Cisplatin Therapy on Advanced and Recurrent Gastric Cancer. K. KANETAKA, A. ENJOJI, J. FURUI, Y. NAGATA, H. FUJIOKA, T. SHIOGAMA, A. MIYATA, H. KISHIKAWA, S. MATSUO, T. IWATA, T. KANEMATSU, S. EGUCHI (The Nagasaki Study Group for Digestive Organ Cancer Chemotherapy) (<i>Nagasaki, Japan</i>)	3495
Subtotal Colectomy for Malignant Left-sided Colon Obstruction Is Associated with a Lower Anastomotic Leak Rate than Segmental Colectomy. S.A. KÄSER, P.M. GLAUSER, B. KÜNZLI, R. DOLANC, G. BASSOTTI, C.A. MAURER (<i>Liestal, Switzerland; Perugia, Italy</i>)	3501
Preliminary Experience on the Use of the Adnatest® System for Detection of Circulating Tumor Cells in Prostate Cancer Patients. T. TODENHÖFER, J. HENNENLOTTER, S. FEYERABEND, S. AUFDERKLAMM, J. MISCHINGER, U. KÜHS, V. GERBER, J. FETISCH, D. SCHILLING, S. HAUCH, A. STENZL, C. SCHWENTNER (<i>Tübingen; Langenhagen, Germany</i>)	3507
Phase II Study of Cisplatin with Irinotecan as Induction Chemotherapy Followed by Chemoradiotherapy for Unresectable Stage III Non-small Cell Lung Cancer. H. CHANG, S.H. KIM, B.C. CHO, S.H. YOON, H.R. KIM, C.G. LEE, J.H. KIM (<i>Seoul, Republic of Korea</i>)	3515
Touch Imprint Cytology and Frozen-section Analysis for Intraoperative Evaluation of Sentinel Nodes in Early Breast Cancer. F. LUMACHI, F. MARINO, S. ZANELLA, G.B. CHIARA, S.M.M. BASSO (<i>Padova; Pordenone, Italy</i>)	3523
Quality of Life in Breast Cancer Patients with Bisphosphonaterelated Osteonecrosis of the Jaws and Patients with Head and Neck Cancer: A Comparative Study Using the EORTC QLQ-C30 and QLQ-HN35 Questionnaires. A. KYRGIDIS, S. TRIARIDIS, K. KONTOS, A. PATRIKIDOU, C. ANDREADIS, J. CONSTANTINIDIS, K. VAHTSEVANOS, K. ANTONIADES (<i>Thessaloniki, Greece; Paris, France</i>)	3527
Elevated Preoperative Inflammatory Markers Based on Neutrophil-to- Lymphocyte Ratio and C-Reactive Protein Predict Poor Survival in Resected Non-small Cell Lung Cancer. M. TOMITA, T. SHIMIZU, T. AYABE, T. ONITSUKA (<i>Miyazaki, Japan</i>)	3535
Dose-dense Intensified Sequential Versus Conventionally-dosed Anthracycline and Taxane-containing Neoadjuvant Therapy in Patients with Inflammatory Breast Cancer. N. DITSCH, A. VODERMAIER, A. HINKE, S. BURGHARDT, M. LENHARD, B. LÖHRS, B. TOTH, F. VON KOCH, S. KAHLERT, I. BAUERFEIND, G.E. KONECNY, S. LOIBL, G. VON MINCKWITZ, M. UNTCH (<i>Munich; Langenfeld; Rosenheim; Landshut; Heidelberg; Neu-Isenburg; Frankfurt; Berlin, Germany; Vancouver, BC, Canada; Santa Monica, CA, USA</i>)	3539

MRI and Ultrasound-guided Prostate Biopsy Using Soft Image Fusion. E. RUD, E. BACO, H.B. EGGESBØ (<i>Aker; Oslo, Norway</i>)	3383
Relapse of Endometrial Carcinoma: Follow-up of 272 Patients with Relapse. B. LINDAHL, J. RANSTAM, R. WILLÉN (<i>Lund; Uppsala, Sweden</i>)	3391
Metastasectomy of Krukenberg Tumors May Be Associated with Survival Benefits in Patients with Metastatic Gastric Cancer. L.-C. LU, Y.-Y. SHAO, C.-H. HSU, C. HSU, W.-F. CHENG, Y.-L. LIN, A.-L. CHENG, K.-H. YEH (<i>Taipei; Yunlin, Taiwan, ROC</i>)	3397
Impact of Immunohistochemical Analysis of Sentinel Lymph Node Biopsy on Breast Cancer Management. E. CHÉREAU, C. BEZU, J. GLIGOROV, R. SAKR, M. ANTOINE, E. DARAI, S. UZAN, R. ROUZIER (<i>Paris, France</i>)	3403
Chaperon Normal Goblet Cells Intercalated with Dysplastic Cells in Duodenal Adenomas Express Synaptophysin. C.A. RUBIO, M. IDESTRÖM (<i>Stockholm, Sweden</i>)	3411
Thalidomide for the Treatment of Myelodysplastic Syndrome in Taiwan: Results of a Phase II Trial. C.-Y. CHUNG, S.-F. LIN, P.-M. CHEN, M.-C. CHANG, W.-Y. KAO, T.-Y. CHAO, L.-T. HSIAO, C.-C. YEN, M.-H. YANG, W.-S. HWANG, T.-L. LIN, T.-J. CHIOU, C.-S. CHANG (<i>Changhua; Kaohsiung; Taipei; Tainan; Taoyuan, Taiwan, ROC</i>)	3415
Association of Location of Lymph Node Metastases with Postoperative Recurrence of Esophageal Squamous Cell Carcinoma. H. TANAKA, M. OHIRA, N. KUBO, K. MUGURUMA, Y. YAMASHITA, T. SAWADA, K. HIRAKAWA (<i>Osaka, Japan</i>)	3421
Impact of Adjuvant Immunochemotherapy Using Protein-bound Polysaccharide-K on Overall Survival of Patients with Gastric Cancer. H. TANAKA, K. MUGURUMA, M. OHIRA, N. KUBO, Y. YAMASHITA, K. MAEDA, T. SAWADA, K. HIRAKAWA (<i>Osaka, Japan</i>)	3427
The mTOR Inhibitor Everolimus in Combination with Carboplatin in Metastatic Breast Cancer – a Phase I Trial. S. SCHWARZLOSE-SCHWARCK, C.W. SCHOLZ, A.C. REGIERER, P. MARTUS, C. NEUMANN, P. HABEL, H. LIU, C. ZANG, J.-H. SCHEFE, C.-O. SCHULZ, K. POSSINGER, J. EUCKER (<i>Berlin, Germany</i>)	3435
Brain Metastasis in a Patient with a Sarcomatoid Variant RCC with Well-controlled Extracerebral Metastases by Temsirolimus. N. KIKUNO, T. KENNOKI, H. FUKUDA, Y. MATSUMOTO, K. TSUNOYAMA, S. BAN, H. SATOH, O. RYOJI (<i>Saitama, Japan</i>)	3443
Acute Liver Failure, Rupture and Hemorrhagic Shock as Primary Manifestation of Advanced Metastatic Disease. G. PREISLER, C. GRAEB, C. STEIB, C.J. ZECH, C. WEILER, H.J. STEMMLER, K.-W. JAUCH, N.H. GRUENER (<i>Munich, Germany</i>)	3449
Decreased Immunoexpression of Standard Form of CD44 Is an Independent Favourable Predictor of Nodal Metastasis in Colorectal Carcinoma. J. AL-MAGHRABI, W. GOMAA, A. BUHMEIDA, M. AL-QAHTANI, M. AL-AHWAL (<i>Jeddah, Saudi Arabia; El Minia, Egypt</i>)	3455
Combination of Core Biopsy and Fine-needle Aspiration Increases Diagnostic Rate for Small Solid Renal Tumors. G. LI, M. CUILLERON, A. ZHAO, F. OBADIA, P. MOURACADE, J. TOSTAIN, M. COTTIER, M. PEOC'H, M. GIGANTE (<i>Saint Etienne, France</i>)	3463
Cell-free DNA Level as a Prognostic Biomarker for Epithelial Ovarian Cancer. J.H. NO, K. KIM, K.H. PARK, Y.-B. KIM (<i>Gyunggi; Seoul, Republic of Korea</i>)	3467

Clinical Significance of Tumor Pathology for Postoperative Survival of Patients Undergoing Surgery for Stage IV Colorectal Cancer. M. ISHIZUKA, H. NAGATA, K. TAKAGI, Y. IWASAKI, N. SHIBUYA, K. KUBOTA (<i>Tochigi, Japan</i>)	3291
Main Effects and Interactions of Carbonic Anhydrase IX, Hypoxia-inducible Factor-1 α , Ezrin and Glucose Transporter-1 in Multivariate Analysis for Disease Outcome in Rectal Cancer. E. KORKEILA, J. SUNDSTRÖM, S. PYRHÖNEN, K. SYRJÄNEN (<i>Turku, Finland</i>)	3299
No Additional Benefit of Adding Ifosfamide to Docetaxel in Castration-resistant Metastatic Prostate Cancer. P. HERVONEN, T. TULIJOKI, P. KELLOKUMPU-LEHTINEN (<i>Tampere, Finland</i>).....	3305
A Case of Paraneoplastic Autoimmune Pancreatitis: Mini-Review of Paraneoplastic Syndromes in Breast Cancer. L. LEKAKIS, D. TRYFONOPOULOS, G. FAKINOS, C. PANOPOULOS, M. THEOCHARI, G. KOUMAKIS, S. DEMIRI, A. EFREMIDIS (<i>Athens, Greece</i>)	3311
Definitive Radiation Therapy for Extramammary Paget's Disease. M. HATA, I. KOIKE, H. WADA, E. MIYAGI, K. ODAGIRI, Y. MINAGAWA, T. KASUYA, H. KAIZU, T. INOUE (<i>Yokohama, Kanagawa, Japan</i>)	3315
Yes-associated Protein Is Not an Independent Prognostic Marker in Breast Cancer. S.-M. SHEEN-CHEN, C.-Y. HUANG, C.-H. TSAI, Y.-W. LIU, S.-C. WU, C.-C. HUANG, H.-L. ENG, Y.-C. CHAN, S.-F. KO, R.-P. TANG (<i>Kaohsiung; Taoyuan, Taiwan</i>)	3321
Oral Cancer in Swedish Snuff Dippers. J.M. HIRSCH, M. WALLSTRÖM, A.-P. CARLSSON, L. SAND (<i>Uppsala; Gothenburg; Västerås, Sweden</i>)	3327
Tumor Angiogenesis in 75 Cases of Pleomorphic Carcinoma of the Lung. Y. TSUBATA, A. SUTANI, T. OKIMOTO, M. MATSUURA, I. MURAKAMI, R. USUDA, T. OKUMICHI, S.-I. KAKEGAWA, K. TOGASHI, S. KOSAKA, Y. YAMASHITA, K. KISHIMOTO, T. KURAKI, T. ISOBE (<i>Izumo, Shimane; Hiroshima; Higashi-Hiroshima; Kure, Hiroshima; Yokohama, Kanagawa; Shibukawa, Gunma; Nagaoka, Niigata, Japan</i>).....	3331
Clinical Significance of Circulating Tumor Cells and Free DNA in Non-small Cell Lung Cancer. K. ISOBE, Y. HATA, K. KOBAYASHI, N. HIROTA, K. SATO, G. SANO, K. SUGINO, S. SAKAMOTO, Y. TAKAI, K. SHIBUYA, K. TAKAGI, S. HOMMA (<i>Tokyo; Saitama, Japan</i>)	3339
Extraskelatal Myxoid Chondrosarcoma of the Left Buccal Mucosa. F. ANGIERO (<i>Genoa, Italy</i>).....	3345
Successful Resection of Esophageal Carcinoma Associated with Double Aortic Arch: A Case Report. N. KUBO, M. OHIRA, Y. YAMASHITA, K. SAKURAI, H. TANAKA, K. MUGURUMA, K. KIMURA, H. NAGAHARA, E. NODA, R. AMANO, M. YASHIRO, K. MAEDA, K. HIRAKAWA (<i>Osaka, Japan</i>)	3351
Splenomegaly During Oxaliplatin-based Chemotherapy for Colorectal Carcinoma. E.-J. JUNG, C.-G. RYU, G. KIM, S.R. KIM, H.S. PARK, Y. J. KIM, D.-Y. HWANG (<i>Seoul, Republic of Korea</i>).....	3357
Mesenchymal Characterization: Alternative to Simple CTC Detection in Two Clinical Trials. G. BARRIERE, A. RIOUALLON, J. RENAUDIE, M. TARTARY, M. RIGAUD (<i>Limoges, France</i>)	3363
Radical Radiotherapy for Superficial Esophageal Cancer: Impact of Clinical N Stage on Survival. T. ARIGA, K. OGAWA, H. SHIMOJI, H. KARIMATA, T. TOITA, Y. KAKINOHANA, G. KASUYA, T. NISHIMAKI, N. YOSHIMI, S. MURAYAMA (<i>Okinawa; Osaka, Japan</i>).....	3371
hGH and GHR Expression in Large Cell Neuroendocrine Carcinoma of the Colon and Rectum. Z. JUKIĆ, R. LIMANI, L. GASHI LUCI, V. NIKIĆ, A. MIJIĆ, D. TOMAS, B. KRUŠLIN (<i>Nova Gradiška; Zagreb, Croatia; Prishtina, Kosovo</i>).....	3377

Elevated Nuclear YB1 Expression Is Associated with Poor Survival of Patients with Early Breast Cancer. A. MACIEJCZYK, J. SZELACHOWSKA, M. EKIERT, R. MATKOWSKI, A. HAŁOŃ, H. LAGE, P. SUROWIAK (<i>Wrocław, Poland; Berlin, Germany</i>)	3177
Reduction of DNA Damage by Curcumin and Celecoxib in Epithelial Cell Cultures of the Oropharynx after Incubation with Tobacco Smoke Condensate. M. REITER, P. BAUMEISTER, D. BOECK, S. SCHWENK-ZIEGER, U. HARRÉUS (<i>Munich, Germany</i>)	3185
Combined Effects of Lapatinib and Cisplatin on Colony Formation of Head and Neck Squamous Cell Carcinoma. C. SCHRADER, A. BOEHM, A. REICHE, A. DIET, C. MOZET, G. WICHMANN (<i>Leipzig, Germany</i>)	3191
Overexpression of Epstein-Barr Virus-encoded microRNA-BART7 in Undifferentiated Nasopharyngeal Carcinoma. J.Y.-W. CHAN, W. GAO, W.-K. HO, W.I. WEI, T.-S. WONG (<i>Hong Kong, PR China</i>)	3201
Establishment and Characterization of a New Human Gallbladder Carcinoma Cell Line. S. SEKINE, Y. SHIMADA, T. NAGATA, M. MORIYAMA, T. OMURA, I. YOSHIOKA, R. HORI, K. MATSUI, S. SAWADA, T. OKUMURA, T. YOSHIDA, K. TSUKADA (<i>Toyama, Japan</i>)	3211
Glyoxalase I (GLO1) is Up-regulated in Pancreatic Cancerous Tissues Compared with Related Non-cancerous Tissues. Y. WANG, Y. KURAMITSU, T. UENO, N. SUZUKI, S. YOSHINO, N. IIZUKA, J. AKADA, T. KITAGAWA, M. OKA, K. NAKAMURA (<i>Ube, Japan</i>)	3219
<i>Clinical Studies</i>	
* Short Review: Role of Androgen Excess in the Development of Estrogen Receptor-positive and Estrogen Receptor-negative Breast Cancer. G. SECRETO, B. ZUMOFF (<i>Milan, Italy; New York, NY, USA</i>)	3223
Gentle Strength Training in Rehabilitation of Breast Cancer Patients Compared to Conventional Therapy. T. SCHMIDT, B. WEISSER, W. JONAT, F.T. BAUMANN, C. MUNDHENKE (<i>Kiel; Cologne, Germany</i>)	3229
* Detection of Human Papillomavirus in Lung Cancer: Systematic Review and Meta-analysis. K. SYRJÄNEN (<i>Turku, Finland; Barretos, SP, Brazil</i>)	3235
Serum Hepatocyte Growth Factor and Interleukin-6 Are Effective Prognostic Markers for Non-small Cell Lung Cancer. H. UJIIE, M. TOMIDA, H. AKIYAMA, Y. NAKAJIMA, D. OKADA, N. YOSHINO, Y. TAKIGUCHI, H. TANZAWA (<i>Saitama; Chiba, Japan</i>)	3251
Neoadjuvant Epirubicin/Docetaxel (ET) Concomitant Chemotherapy for Primary Breast Cancer with Tumor Diameter ≥ 3.1 cm: Results of the Kyushu ET Therapy Phase II Trial. R. NISHIMURA, Y. RAI, F. MATSUO, K. ANAN, S. HARA, S. IMAMURA, N. ITOYANAGI, M. KATO, M. OKIDO, M. KUDAKA, E. ISHIKAWA, Y. KAMADA, R. WATANABE, M. SHIROUZU, S. MITSUYAMA, Y. TAKAMATSU, K. TAMURA (<i>Kumamoto; Kagoshima; Fukuoka; Nagasaki; Okinawa; Miyazaki, Japan</i>)	3259
Biochemical Failure after Carbon Ion Radiotherapy for Prostate Cancer. J. SHIMAZAKI, H. TSUJI, H. ISHIKAWA, T. KAMADA, M. HARADA, K. AKAKURA, H. SUZUKI, T. ICHIKAWA, H. TSUJII (<i>Chiba; Yokohama, Japan</i>)	3267
Clinical Significance of Chemoradiotherapy and Surgical Resection for cT4 Esophageal Cancer. M. MORITA, Y. TOH, H. SAEKI, M. SUGIYAMA, K. OHGAKI, S.-I. MAEHARA, K. MINAMI, Y. IKEDA, Y. SAKAGUCHI, T. OKAMURA, S. UEHARA, Y. MAEHARA (<i>Fukuoka, Japan</i>)	3275
Dexamethasone plus Somatostatin-analog Manipulation as Bone Metastasis Microenvironment-targeting Therapy for the Treatment of Castration-resistant Prostate Cancer: A Meta-analysis of Uncontrolled Studies. K.A. TOULIS, D.G. GOULIS, P. MSAOUEL, M. KOUTSILIERIS (<i>Thessaloniki; Athens, Greece; Bronx, NY, USA</i>)	3283

Aromatase in Colon Carcinoma. R. SATO, T. SUZUKI, Y. KATAYOSE, K. MIURA, K. SHIIBA, Y. MIKI, Y. KAMOGAWA, K. YAMAMOTO, T. II, S. EGAWA, M. UNNO, H. SASANO (<i>Sendai; Natori, Japan</i>)	3069
* Review: Tumor Progression and Metastasis: Role of Translational Deregulation. Z. NASR, J. PELLETIER (<i>Montreal, QC, Canada</i>)	3077
Human Papillomavirus DNA and <i>p16</i> Gene in Squamous Cell Lung Carcinoma. L. BENERINI GATTA, P. BALZARINI, A. TIRONI, A. BERENZI, A. BENETTI, F. ANGIERO, P. GRIGOLATO, E. DESSY (<i>Brescia; Genoa, Italy</i>)	3085
Gene Amplification of <i>ZNF217</i> Located at chr20q13.2 is Associated with Lymph Node Metastasis in Ovarian Clear Cell Carcinoma. M.T. RAHMAN, K. NAKAYAMA, M. RAHMAN, H. KATAGIRI, A. KATAGIRI, T. ISHIBASHI, M. ISHIKAWA, K. IIDA, N. NAKAYAMA, Y. OTSUKI, S. NAKAYAMA, K. MIYAZAKI (<i>Shimane; Hamamatsu, Japan</i>)	3091
PKC α Suppresses 7,12-Dimethylbenz[<i>a</i>]anthracene-induced Skin Tumor Formation. T. HARA, S. MATSUMURA, F. HAKUNO, S.-I. TAKAHASHI, K. CHIDA (<i>Tokyo, Japan</i>)	3097
β -Elemene Effectively Suppresses the Growth and Survival of both Platinum-sensitive and -resistant Ovarian Tumor Cells. R.X. LEE, Q.Q. LI, E. REED (<i>Morgantown, WV; Bethesda, MD, USA</i>)	3103
The Length of the Barrett's Mucosa in Baboons, Revisited. C.A. RUBIO, J.R. NILSSON, M. OWSTON, E.J. DICK JR. (<i>San Antonio, TX, USA</i>)	3115
Cell-free Serum DNA in Patients with Bladder Cancer: Results of a Prospective Multicenter Study. S. HAUSER, M. KOGEJ, G. FECHNER, A. VON RUECKER, P.J. BASTIAN, J. VON PEZOLD, R. VORREUTHER, G. LÜMMEN, S.C. MÜLLER, J. ELLINGER (<i>Bonn; Munich; Lindlar; Troisdorf, Germany</i>)	3119
Screening for Cytotoxic Compounds in Poor-prognostic Chronic Lymphocytic Leukemia. M. NORBERG, E. LINDHAGEN, M. KANDURI, L. RICKARDSON, C. SUNDSTRÖM, K. STAMATOPOULOS, R. ROSENQUIST, A. ÅLESKOG (<i>Uppsala, Sweden; Thessaloniki, Greece</i>)	3125
Improved Gene Transfer into Bladder Cancer Cells Using Adenovirus Vector Containing RGD Motif. K. HIWASA, H. NAGAYA, S. TERAU, B. ACHARYA, K. HAMADA, H. MIZUGUCHI, A. GOTOH (<i>Nishinomiya; Matsuyama; Osaka, Japan</i>)	3137
PI3K/mTOR Signaling Pathways in Medulloblastoma. A.L. MOHAN, M.D. FRIEDMAN, D.R. ORMOND, M. TOBIAS, R. MURALI, M. JHANWAR-UNIYAL (<i>Valhalla, NY, USA</i>)	3141
The Expression of FHIT in Salivary Carcinoma Ex Pleomorphic Adenoma. O. KUJAN, B. TARAKJI, N. THAKKER, A.A. AL KHERAIF, P. SLOAN (<i>Riyadh, Saudi Arabia; Hama; Aleppo, Syria; Manchester; Newcastle upon Tyne, UK</i>)	3147
Preservation of <i>HUGL-1</i> Expression as a Favourable Prognostic Factor in Pancreatic Carcinoma. S. BIESTERFELD, A. KAUSAUSEN, C. KOST, I. GOCKEL, C.C. SCHIMANSKI, P.R. GALLE (<i>Düsseldorf; Mainz, Germany</i>)	3153
HDAC Inhibitors Synergize Antiproliferative Effect of Sorafenib in Renal Cell Carcinoma Cells. M.J. KIM, D.E. KIM, I.G. JEONG, J. CHOI, S. JANG, J.-H. LEE, S. RO, J.J. HWANG, C.-S. KIM (<i>Seoul; Gyeonggi-Do, Republic of Korea</i>)	3161
Prognostic Significance of Glutathione Peroxidase 1 (<i>GPX1</i>) Down-regulation and Correlation with Aberrant Promoter Methylation in Human Gastric Cancer. S.Y. MIN, H.S. KIM, E.J. JUNG, E.J. JUNG, C.D. JEE, W.H. KIM (<i>Seoul; Incheon, Republic of Korea</i>)	3169